The pRPa
ISL plasmid [25] (
link) was redesigned
in silico to contain two, inverted Gateway donor sites (containing attP sites and a
ccdB counter selectable marker) separated by 150 bp of the
lacZ gene. This modification was synthesised (Blue Heron Biotech) and cloned between the
BamHI and
XbaI sites of pRPA
ISL. The resultant plasmid, termed pGL2084, was propagated in
ccdB Survivor cells (Invitrogen) at 25°C. RNAi target sequences were determined for the CDS of each PK gene using the TrypanoFAN: RNAit programme [47] (
link). RNAi targets were amplified from
T. b. brucei TREU 927 genomic DNA using Phusion high fidelity polymerase (NEB, Massachusetts) with appropriate oligonucleotide pairs (
Table S3) incorporating attB1 and attB2 sites before being cloned into pGL2084 in a BP Recombinase reaction (Invitrogen) as per the manufacturer's instructions. 12 PKs were cloned into unmodified pRPa
ISL (indicated in
Table S1). The resultant plasmids (pTL) were propagated using DH5α Max Efficiency cells, and purified and digested with
AscI (NEB) prior to transfection.
T. b. brucei 2T1 BSF cells and derivatives were maintained in HMI-11 (HMI-9 (GIBCO), 10% v/v foetal calf serum (FCS; GIBCO 10270), Pen/Strep (SIGMA) (penicillin 20 Uml
−1, streptomycin 20 µgml
−1)), at 37°C, 5% CO
2 in vented flasks [48] (
link). Appropriate selective drugs were added at the following concentrations: 2 µg ml
−1 puromycin, 2.5 µg ml
−1 phleomycin (InvivoGen), 5 µg ml
−1 hygromycin B (Calbiochem) and 10 µg ml
−1 blasticidin (InvivoGen). BSF parasites were transfected as previously described [27] (
link), with independent clones obtained by limiting dilution. Clones were screened for puromycin sensitivity [25] (
link); puromycin sensitive clones were prioritised for further analyses.
In order to specifically target each individual
NEK12 mRNA, the
NEK12.1 and
NEK12.2 genes were aligned and short regions (over 20 nt) were identified where enough divergence existed to enable gene specific silencing by RNAi. For each gene, five small fragments (targeting the equivalent regions of each gene) were identified and joined
in silico, then synthesised into attB flanked inserts (Genscript) ready for Gateway cloning into pGL2084. CLK1/2 individual RNAi constructs were generated by targeting the diverged 5′ region of the CDS and 5′ UTR.
Jones N.G., Thomas E.B., Brown E., Dickens N.J., Hammarton T.C, & Mottram J.C. (2014). Regulators of Trypanosoma brucei Cell Cycle Progression and Differentiation Identified Using a Kinome-Wide RNAi Screen. PLoS Pathogens, 10(1), e1003886.